Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET
Company Participants
Ted Jenkins - Vice President, Investor Relations and Strategic Finance
Sath Shukla - Chief Executive Officer
Kamal Hamed - Chief Medical Officer
Steve Dipalma - Interim Chief Financial Officer and Treasurer
Conference Call Participants
Louise Chen - Cantor
Boobalan Pachaiyappan - H.C. Wainwright
Ritu Baral - Cowen
Operator
Good afternoon and welcome to the Spero Therapeutics Second Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please be advised that this call is being recorded and a replay will be available. You can find information on the replay and further information related to today’s announcements on the Spero Therapeutics website at www.sperotherapeutics.com. At this time, I would like to turn the call over to Ted Jenkins, Vice President, Investor Relations and Strategic Finance at Spero Therapeutics. Mr. Jenkins, please go ahead.
Ted Jenkins
Thank you, operator and thank you all for participating in today’s conference call. This afternoon, Spero Therapeutics released financial results and provided a pipeline update for the second quarter of 2023. Our press release is available on the Investor page of the Spero Therapeutics website.
Before we begin, I’d like to remind you that some of the information presented on this conference call contains forward-looking statements based on our current expectations, including statements about the future development and commercialization at Tebipenem HBr, SPR720, SPR206 and the design, initiation, timing, progress and results of the company’s preclinical studies and clinical trials and its research and development programs. Management’s assessment of the results of such preclinical studies and clinical trials, the company’s cash forecast and anticipated expenses and the sufficiency of its cash resources. Such forward-looking statements are not a guarantee of performance and the company’s actual results could differ materially from those contained in such statements.
Several factors that could cause or contribute to such differences are described in detail in Spero Therapeutics’ filings with the SEC, including in the Risk Factors section of our quarterly report on Form 10-Q for the quarter ended June 30, 2023 filed with the SEC today. These forward-looking statements speak only as of the date of this conference call and the company undertakes no obligation to publicly update any forward-looking statements or supply new information regarding the company after the date of today’s call.
With that, I’d like to turn the call over to Spero’s Chief Executive Officer, Sath Shukla. Please go ahead, Sath.